Effect of single oral administration of YM598, a novel selective endothelin ETA receptor antagonist, on blood pressure in normotensive and hypertensive rats

Vascular Pharmacology

Volumn 41, Issue 1, 2004, Pages 27-34

  Yuyama, Hironori ^a   Sonoda, Rie ^a   Shibasaki, Kumiko ^a   Fujimori, Akira ^a   Sudoh, Katsumi ^a   Sasamata, Masao ^a   Miyata, Keiji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Dahl salt sensitive hypertensive rats; Nifedipine; Normotensive rats; Selective endothelin ETA receptor antagonist; Spontaneously hypertensive rats; YM598

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; ENDOTHELIN A RECEPTOR ANTAGONIST; NIFEDIPINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; YM 598;

ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HYPERTENSION; HYPOTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; DRUG ADMINISTRATION SCHEDULE; HYPERTENSION; MALE; PYRIMIDINES; RATS; RATS, INBRED DAHL; RATS, INBRED SHR; RATS, WISTAR; RECEPTOR, ENDOTHELIN A; SULFONAMIDES;

EID: 2342507585     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2004.03.004     Document Type: Article

References (31)

1. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 348(6303):1990;730-732
2. Balakrishnan S.M., Wang H.D., Gopalakrishnan V., Wilson T.W., McNeill J.R. Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension. 28(5):1996;806-809
3. Barton M., d'Uscio L.V., Shaw S., Meyer P., Moreau P., Luscher T.F. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension. 31(1 Pt. 2):1998;499-504
4. Dahl L.K., Heine M., Tassinari L. Effects of chronic salt ingestion: evidence that genetic factors play an important role in susceptibility to experimental hypertension. J. Exp. Med. 115:1962;1173-1190
5. Doucet J., Gonzalez W., Michel J.B. Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency. J. Cardiovasc. Pharmacol. 27(5):1996;643-651
6. Douglas S.A., Gellai M., Ezekiel M., Ohlstein E.H. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J. Hypertens. 12(5):1994;561-567
7. d'Uscio L.V., Barton M., Shaw S., Moreau P., Luscher T.F. Structure and function of small arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A-receptor blockade. Hypertension. 30(4):1997;905-911
8. Garthoff B., Kazda S., Knorr A., Thomas G. Factors involved in the antihypertensive action of calcium antagonists. Hypertension. 5(4 Pt. 2):1983;II34-II38
9. 2+ channel in vascular smooth muscle. Proc. Natl. Acad. Sci. U. S. A. 86:1989;3915-3918
10. Hocher B., Rohmeiss P., Zart R., Diekmann F., Vogt V., Metz D., Fakhury M., Gretz N., Bauer C., Koppenhagen K. Significance of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats: renal and hemodynamic effects of endothelin receptor antagonists. J. Cardiovasc. Pharmacol. 26(S3):1995;S470-S472
11. Ikeda T., Ohta H., Okada M., Kawai N., Nakao R., Siegl P.K., Kobayashi T., Maeda S., Miyauchi T., Nishikibe M. Pathophysiological roles of endothelin-1 in Dahl salt-sensitive hypertension. Hypertension. 34(3):1999;514-519
12. Intengan H.D., Schiffrin E.L. Mechanical properties of mesenteric resistance arteries from Dahl salt-resistant and salt-sensitive rats: role of endothelin-1. J. Hypertens. 16(112 Pt. 2):1998;1907-1912
13. Iwanaga Y., Kihara Y., Hasegawa K., Inagaki K., Yoneda T., Kaburagi S., Araki M., Sasayama S. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation. 98(19):1998;2065-2073
14. Jee L.D., Opie L.H. Acute hypotensive response to nifedipine added to prazosin in treatment of hypertension. Br. Med. J. 287(6404):1983;1514-1515
15. Karam H., Heudes D., Bruneval P., Gonzales M.F., Loffler B.M., Clozel M., Clozel J.P. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension. 28(3):1996;379-385
16. Kassab S., Novak J., Miller T., Kirchner K., Granger J. Role of endothelin in mediating the attenuated renal hemodynamics in Dahl salt-sensitive hypertension. Hypertension. 30(3 Pt. 2):1997;682-686
17. Kassab S., Miller M.T., Novak J., Reckelhoff J., Clower B., Granger J.P. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension. 31(1 Pt. 2):1998;397-402
18. Li J.S., Schiffrin E.L. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension. 25(4 Pt. 1):1995;495-500
19. Miyauchi T., Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu. Rev. Physiol. 61:1999;391-415
20. Moreau P. Endothelin in hypertension: a role for receptor antagonists? Cardiovasc. Res. 39(3):1998;534-542
21. Nishikibe M., Tsuchida S., Okada M., Fukuroda T., Shimamoto K., Yano M., Ishikawa K., Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 52(8):1993;717-724
22. Ohlstein E.H., Douglas S.A. Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug Dev. Res. 29:1993;108-128
23. A receptor antagonist, J-105859. J. Hypertens. 18(12):2000;1815-1823
24. Okamoto K., Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn. Circ. 27:1963;282-293
25. Pasanisi F., Elliott H.L., Meredith P.A., McSharry D.R., Reid J.L. Combined alpha adrenoceptor antagonism and calcium channel blockade in normal subjects. Clin. Pharmacol. Ther. 36(6):1984;716-723
26. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 348:1990;732-735
27. Sakurai T., Yanagisawa M., Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol. Sci. 13:1992;103-108
28. Sharma J.N., Fernandez P.G., Laher I., Triggle C.R. Differential sensitivity of Dahl salt-sensitive and Dahl salt-resistant rats to the hypotensive action of acute nifedipine administration. Can. J. Physiol. Pharm. 62(2):1984;241-243
29. Warner T.D., Mitchell J.A., de Nucci G., Vane J.R. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J. Cardiovasc. Pharmacol. 13(S5):1989;S85-S88
30. Yangisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415
31. A receptor antagonist. Eur. J. Pharmacol. 478:2003;61-71